US1628282063 - Common Stock
CHECKPOINT THERAPEUTICS INC
NASDAQ:CKPT (4/22/2024, 7:00:00 PM)
After market: 1.52 +0.07 (+4.83%)1.45
-0.01 (-0.68%)
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is headquartered in Waltham, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2016-11-02. The firm is evaluating its lead antibody product candidate, cosibelimab, which is an anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute (Dana-Farber) in an ongoing global, open-label, multicohort Phase I clinical trial in checkpoint therapy-naive patients with selected recurrent or metastatic cancers including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) intended to support one or more applications for marketing approval. In addition, it is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, which is an epidermal growth factor receptor (EGFR) inhibitor as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).
CHECKPOINT THERAPEUTICS INC
95 Sawyer Road, Suite 110
Waltham MASSACHUSETTS 10014
P: 17816524500
CEO: James F. Oliviero
Employees: 24
Website: https://checkpointtx.com/
WHY: NEW YORK, NY - (NewMediaWire) - April 22, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”), of the important June 4, 2024 lead plaintiff deadline.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
WHY: NEW YORK, NY - (NewMediaWire) - April 21, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”), of the important June 4, 2024 lead plaintiff deadline.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
WHY: NEW YORK, NY - (NewMediaWire) - April 20, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”), of the important June 4, 2024 lead plaintiff deadline.
Here you can normally see the latest stock twits on CKPT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: